Corbus Pharmaceuticals Holdings, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for CRBP, updated each market day.
CRBP AI Sentiment
AI sees no strong directional signal for Corbus Pharmaceuticals Holdings, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Sector
Exchange
Market Cap
$183,040,308
Cap Tier
Employees
36
Headquarters
NORWOOD, MA
Listed Since
Oct. 24, 2014
Website
CRBP Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CRBP Volatility
Corbus Pharmaceuticals Holdings, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
